Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will pa...
Cullinan Oncology ( NASDAQ: CGEM ) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application seeking to start a trial of blood cancer drug CLN-978. The company will initially evaluate CLN-978 in a phase 1 trial to treat patients with ...
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) app...
Cullinan Oncology press release ( NASDAQ: CGEM ): Q3 GAAP EPS of -$0.54 beats by $0.43 . Cash and investments of approximately $607 million as of September 30, 2022 For further details see: Cullinan Oncology GAAP EPS of -$0.54 beats by $0.43
Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN-049 and CLN-619 clinical studies with initial clinical data updates on track for mid-20...
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointe...
Cullinan Oncology ( NASDAQ: CGEM ) on Tuesday said it increased its ownership in its subsidiary Cullinan MICA (MICA) to 92% from 54% for $30.7M. Cullinan raised its ownership by buying equity from two of MICA's financial investors, Avalon Ventures and Br...
Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial investors The ongoing Phase I clinical trial for CLN-619 remains on track to report initial clinical data in mid-2023 CAMBRIDGE, Mass., Oct. 25, 2022 (GLOBE NEWSW...
Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ...
Summary Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after. Robust cash position (runway through 2026) allows them to prosecute clinical programs more...
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
2024-06-30 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivanta...
2024-05-29 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...